Sarepta Therapeutics, Inc. — 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020; the filing also presents unaudited fourth-quarter results. Sarepta is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, gene therapy and other genetic medicines for rare diseases, principally Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs).
Financial performance and liquidity
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Product revenue | $455.9 million | $380.8 million | 20% increase |
| Collaboration revenue | $84.2 million | — | New in 2020 |
| Total revenue | $540.1 million | $380.8 million | 42% increase |
| Operating loss | $564.2 million | $705.6 million | 20% improvement |
| Net loss | $554.1 million | $715.1 million | 23% improvement |
| Net loss per share | $7.11 | $9.71 | Improved by $2.61 |
| Cash provided by operating activities | $107.5 million | $(456.5) million | Improved by $563.9 million |
| Cash, cash equivalents and investments | $1.948 billion | $1.134 billion | 72% increase |
| Total borrowings, carrying value | $992.5 million | $681.9 million | 46% increase |
Research and development expense increased 29% to $722.3 million, driven primarily by manufacturing and development activity for the SRP-9001 micro-dystrophin program and other gene therapy programs. Selling, general and administrative expense increased 12% to $317.9 million. Cost of sales, including amortization of in-licensed rights, was approximately $64.0 million, implying an approximate total-revenue gross margin of 88%; the filing does not present gross margin as a reported metric. Operating and net margins remained materially negative, at approximately negative 104% and negative 103%, respectively.
Year-end liquidity included $1.503 billion of cash and cash equivalents, $435.9 million of short-term investments and $9.3 million of restricted cash and investments. Management stated that liquidity was sufficient to fund the current operating plan for at least the next twelve months, while also noting that additional financing may be required.
Material changes versus 2019
- Product revenue rose $75.0 million, primarily reflecting increased U.S. demand and the launch of VYONDYS 53 in December 2019.
- The Roche collaboration generated $84.2 million of revenue in 2020. Roche provided approximately $1.2 billion of consideration, consisting of $750.0 million in cash and approximately $400.0 million for 2,522,227 Sarepta shares. A substantial portion remains deferred and is being recognized over the expected performance period through the fourth quarter of 2023.
- Roche reimbursed approximately $66.5 million of eligible costs in 2020, including $65.9 million recorded as a reduction of research and development expense.
- R&D spending increased $161.4 million, with micro-dystrophin spending rising to $289.9 million from $84.5 million and manufacturing expense increasing 157% to $366.9 million.
- Operating loss narrowed despite higher development spending because of increased product and collaboration revenue and the absence of the $173.2 million Myonexus acquired in-process research and development charge recorded in 2019.
- Cash flow from operations turned positive largely because of the Roche-related increase in deferred revenue; this does not represent recurring operating profitability.
- Total debt increased following the November 2020 draw of the $300.0 million Tranche B term loan. Principal debt consisted primarily of $550.0 million of term loans and approximately $570.0 million of convertible notes.
Outlook, commentary, risks and unusual items
- Management expected significant operating losses to continue at least through 2021 and did not provide clear numeric revenue or profitability guidance.
- Key development milestones cited for 2021 and beyond included additional SRP-5051 data, SRP-9001 Study 103 biomarker and safety results, completion of SRP-9003 GMP runs and seeking FDA confirmation to initiate an SRP-9003 pivotal trial.
- EXONDYS 51 and VYONDYS 53 remained subject to accelerated-approval post-marketing requirements. Continued approval depends on confirmatory evidence of clinical benefit, creating regulatory and commercial risk.
- COVID-19 disrupted patient infusions, insurance reauthorizations, clinical-trial enrollment and monitoring, manufacturing and other operations. Management expected the pandemic to reduce revenue and cash flows, although the filing does not quantify the impact.
- Sarepta relies heavily on third-party manufacturers and has substantial manufacturing commitments. Contractual obligations totaled $2.673 billion, including $1.294 billion of manufacturing commitments and $1.321 billion of debt obligations, including interest.
- The company disclosed up to approximately $3.9 billion of potential future milestone, royalty and other contingent payments under license and collaboration agreements; these amounts were not recorded because the applicable milestones were not probable as of year-end.
- Sarepta recorded a $108.1 million gain from selling a Priority Review Voucher and a $45.0 million loss from revaluing contingent consideration. These items materially affected reported earnings but are not indicative of recurring operations.
- RegenXBIO and the University of Pennsylvania sued Sarepta in September 2020 alleging patent infringement related to AAV manufacturing technology, including SRP-9001. Sarepta moved to dismiss, and the filing states that a potential loss could not be estimated.
- After year-end, the FDA granted accelerated approval to AMONDYS 45 on February 25, 2021. The subsequent event was not a 2020 commercial product approval. Sarepta also agreed to sell the related Priority Review Voucher for $102.0 million, subject to closing conditions.
Most important facts for investors to verify
- Whether revenue growth from EXONDYS 51 and VYONDYS 53 is sustainable amid COVID-19, reimbursement restrictions and competing DMD therapies.
- The composition and timing of Roche deferred revenue recognition, cost reimbursements, potential option exercises, milestones and future royalties.
- Clinical and regulatory results supporting the accelerated approvals and the development prospects of SRP-9001, SRP-9003 and SRP-5051.
- Whether third-party manufacturing capacity, quality controls and supply commitments can support commercial and clinical demand.
- Debt maturities, interest costs, covenant requirements and the company’s ability to fund operations without additional dilutive or restrictive financing.
- The potential financial and operational effect of the RegenXBIO patent litigation and other intellectual-property disputes.
- The recoverability of inventory and other assets, particularly given the company’s reliance on evolving gene therapy programs and the critical audit matter concerning raw-material inventory valuation.